52 results about "Cell bank" patented technology

The application discloses a low-orbit satellite congestion control method based on an artificial immune algorithm, which comprises the following steps: a satellite node periodically monitors the occupancy rate of an output queue in each direction, when congestion is detected, the satellite generates a congestion warning packet as an antigen and sends it to a directly adjacent node; the adjacent node receiving the congestion warning packet finds a matching item of an affected destination node in a historical memory cell library through the similarity between the current scene and the historical record, as the routing strategy of the destination node; when no match is found, the optimal bypass strategy is determined based on the direction of the congestion link and the position information of the satellite; the satellite comprehensively evaluates the generated control strategy within a time window; when the affinity continues to fail to reach a threshold, the satellite continuously monitors the queue occupancy rate change trend, and when it is found that a continuous multiple periods show an upward trend, the shunt proportion is increased; the application improves the response speed of the congestion control, network performance and service quality.

A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.

This invention relates to the interdisciplinary field of cell biology, experimental oncology, and translational medicine, specifically to a cancer-associated fibroblast cell line, its construction method, and its applications. This invention fills the research gap in mouse-derived oral squamous cell carcinoma-associated fibroblast cell line models and provides a method for constructing such a cell line. Through the inverted adherent culture and enzymatic digestion methods of this invention, a mouse-derived oral squamous cell carcinoma-associated fibroblast cell line with a clear origin, high purity, and long-term phenotypic and functional stability can be obtained. This allows for the establishment of a cryopreservable and resuscitable mouse oral squamous cell carcinoma-associated fibroblast cell bank, providing technical support for research related to the tumor microenvironment and immunotherapy.

This vector set is induced into host cells, and cells for producing heteromultimeric proteins are selected from the host cells into which has the vector set is introduced. vector set is a set of a first expression vector and a second expression vector, wherein an expression cassette of at least one subunit X which is a part of a subunit constituting a heteromultimeric protein is contained in both the first expression vector and the second expression vector and from among the subunits constituting the heteromultimeric protein, an expression cassette of the remaining subunit Y excluding the subunit X is contained for each type in one among the first expression vector and the second expression vector.

The invention discloses a line establishment method and a culture system of bovine trophoblast stem cells. The stem cell line is obtained by separation and induction from bovine blastocyst. The embryonic stem cell line has stability. The method can be applied to various life science and medical fields such as bovine animal breeding and breeding, gene editing models, animal cloned donor cells, medical musculoskeletal injury experiments, drug development carriers, vaccine production cell banks, embryo quality analysis and the like, and can be applied to large-scale production and application.

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

The invention discloses a human gallbladder cancer cell line and application thereof. The human gall bladder cancer cell line comprises a human gall bladder cancer cell JXQ-3D-8529R1 or a human gall bladder cancer cell JXQ-3D-8529R2; the human gallbladder cancer cell JXQ-3D-8529R1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human gallbladder cancer cell JXQ-3D-8529R1 is CCTCC NO: C2023372; the preservation number of the human gallbladder cancer cell JXQ-3D-8529R2 is CCTCC (China Center For Type Culture Collection) NO: C2023371. The human gallbladder cancer cells JXQ-3D-8529R1 and JXQ-3D-8529R2 can be massively amplified, can be subcultured in vitro for a long time, have different sensitivities to cis-platinum, gemcitabine and the like, enrich a human gallbladder cancer cell bank, and provide a new test material for revealing the occurrence and development mechanism of gallbladder cancer and preclinical research of corresponding drug development.

A method is derived for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of antibody producing cell libraries such as B-cell and hybridoma libraries. Specifically, the method relates to application of reversed immunocapture and high resolution tandem mass spectrometry for the identification of heavy and light chain pairs of binding antibodies obtained from high throughput screens of antibody producing cell libraries.

To provide compositions for determining the efficacy and potency of a vaccine preparation.SOLUTION: Splenocytes from immunized animals are isolated and frozen. Upon thawing aliquots, these cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are counted, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and / or potency.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of molecular biology, and particularly relates to a nucleic acid sequence combination for mycoplasma detection, a kit and a use method of the kit. The detection kit comprises a PCR (Polymerase Chain Reaction) specific primer probe, a buffer solution, Taq enzyme and an internal quality control (IC), wherein the primer probe comprises forward and reverse amplification primers aiming at mycoplasma and an internal standard and a detection probe; the sequences of the primers are shown as SEQ ID NO.1-SEQ ID NO.7 respectively. The kit disclosed by the invention can be used for detecting mycoplasmas and accurately identifying whether various biological samples such as cell banks, production raw materials, virus seeds, cell cultures and the like are polluted by the mycoplasmas, and has high sensitivity, specificity and detection accuracy. Meanwhile, by adding internal quality control (IC), whether the to-be-detected sample inhibits the amplification reaction or not can be judged, and a false negative result is prevented from being generated.

The present invention relates to a method for mass-producing, with high-purity and high-efficiency, extracellular vesicles by using a novel cell bank construction strategy, and extracellular vesicles produced therefrom. According to one embodiment of the present invention, extracellular vesicles can be mass-produced with high purity and high efficiency while the characteristics of genetically modified or unmodified cells are stably maintained through the construction of a novel cell bank, and the produced extracellular vesicles can be effectively used as a pharmaceutical composition for preventing or treating diseases and a functional cosmetic composition.

This application discloses a muscle stem cell resuscitation and protection washing solution, a quality assessment kit, and a method of use, belonging to the field of cell biology technology. In this application, vitamin E succinate and mannan peptide are used as core antioxidant components, synergistically combined with Gynostemma pentaphyllum polysaccharide, Portulaca oleracea polysaccharide, trehalose, L-proline, and magnesium sulfate heptahydrate to construct a four-in-one resuscitation and protection washing solution that provides isotonic buffering, extracellular protection, intracellular protein stabilization, antioxidant effects, and mitochondrial stabilization. This increases the survival rate of muscle stem cells after resuscitation to over 93%. The kit integrates a multi-dimensional detection system for cell resuscitation and protection washing solution, cell viability, proliferation rate, Pax7 / MyoD double-positive stemness assessment, and cryopreservation damage, achieving closed-loop management of the entire process of muscle stem cell resuscitation, protection, and quality assessment. The double-positive rate of stemness markers reaches over 90%, providing reliable quality assurance for cell bank management and clinical applications.

The present disclosure relates to a method for producing mesenchymal stem cells for therapeutic applications. The method comprises culturing of MSCs to obtain heterogeneous population. This heterogeneous population of MSCs were subjected to droplet encapsulation media to obtain a population of microfluidic droplets preferably comprising a single MSC; providing the population of microfluidic droplets to a microfluidics device; and identifying and selecting a homogeneous population of MSCs having medium size in the range of 15 to 30 μm showing high expression of cell surface markers (CD73, CD90) and increased expression of genes, such as COL12 A1; IGFBP5; THBS2; GREM1 and CDH2 genes. The MSCs having medium size are further cryopreserved to obtain a cell bank of MSCs with better stability and therapeutic potential in treating diseases like auto immune diseases.

The invention discloses a stem cell culture generation identification method based on an epigenetics clock. Belongs to the field of biotechnology and molecular biology, and designs a specific multiple PCR primer pool and establishes a high-precision generation prediction model by screening eight CpG sites highly related to stem cell replicative senescence. The method comprises the following steps: firstly, carrying out hydrosulfite conversion on sample DNA (Deoxyribonucleic Acid), carrying out targeted amplification by adopting a primer group with an optimized ratio, calculating a methylation level through high-throughput sequencing, and substituting into a formula to output a result. The model has small mean absolute error and is significantly related to aging function indexes. Compared with traditional chip detection, the cost is reduced, the detection period is shortened, and the method is suitable for release inspection of stem cell treatment products, anti-aging drug screening and cell bank quality management.

The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.

The present invention discloses a method for screening, activating, amplifying and cryopreserving mesenchymal stem cells in vitro and establishing a cell bank of mesenchymal stem cells. The method includes the following steps: using a dedicated primary screening medium of mesenchymal stem cells for first-stage screening culture to obtain purified mesenchymal stem cells; using a dedicated activation and amplification medium of mesenchymal stem cells to perform second-stage activation and large-scale amplification culture on the purified mesenchymal stem cells to obtain a large number of mesenchymal stem cells with activation functions; using a dedicated cryopreserving fluid of mesenchymal stem cells to cryopreserve the stem cells and performing preservation according to ABO / RH typing and HLA typing; and establishing an information file for retrieval to construct a mesenchymal stem cell bank.

Described herein are methods for testing the differentiability of pluripotent stem cells (PSCs). The methods comprise assaying PSCs or PSC populations for differentiability marker mutation(s) and / or expression and determining the suitability of the PSCs or PSC populations for differentiation, e.g., into a product suitable for cell therapy. The methods can be used in cell banking and manufacturing cell therapies. Also provided herein are kits suitable for performing the PSC differentiability assessment methods disclosed herein.

The invention discloses a suspension culture cell monoclonal screening culture method. The method comprises the following steps: selecting cells under suspension culture conditions and inducing the cells to recover adherence; separating the single cells developed into obvious clones, and carrying out radioactive ray irradiation on the remaining cells, so that the remaining cells lose the multiplication capacity and become feeder layer cells; culturing the separated monoclonal cells, recording the culture time and culture environment, establishing a high-density cell bank, and establishing a growth time prediction formula for the multiple monoclonal cells according to the culture time; and calculating the specific time for culturing the required number of cells according to the growth time prediction formula established in the step S3. According to the method, the remaining cells are subjected to radioactive ray irradiation and are converted into feeder layer cells with important effects, so that the waste of cell resources is avoided, the flexible utilization of the cell resources is realized, and the treatment cost of the remaining cells is also remarkably reduced.

In the various aspects and embodiments, the present disclosure provides cell populations or cell “banks” thereof to provide immune compatible, allogeneic cell therapies. In the various aspects and embodiments, the cell populations and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the populations by gene editing, and methods for cell therapy involving cells or tissues derived from the cell populations (including but not limited to hematopoietic stem cells, or “HSCs”, progenitors, or progenies thereof).

This invention relates to a method for evaluating the wound-healing efficacy of mesenchymal stem cell (MSC) populations. Furthermore, this invention relates to a method for selecting MSCs for generating stem cell populations under cGMP conditions, and a method for selecting MSC populations for generating stem cell populations for subsequent drug administration. Additionally, this invention relates to a method for selecting MSC populations for generating a master cell bank, and a method for identifying tissues suitable as starting materials for generating MSC populations for drug use. The method includes measuring the levels of at least two proteins selected from angiopoietin-1 (Ang-1), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) secreted by MSCs into the culture medium.

The invention discloses a hydrogen leakage diagnosis method and device based on multi-modal information combination, and relates to the technical field of industrial safety monitoring and fault diagnosis, and the method comprises the steps: determining whether hydrogen concentration data exceeds a set concentration threshold value or not; if the hydrogen concentration data exceeds a set concentration threshold value, acquiring multi-modal information data in real time; if the hydrogen concentration data does not exceed the set concentration threshold value, processing is not carried out; determining an acoustic confidence map, an optical confidence map and an infrared confidence map; determining a fusion weight parameter based on the environment information data and the memory cell bank, and further obtaining a fusion confidence map and a weighted fusion feature vector; determining a hydrogen leakage position based on the fusion confidence map; adopting a multi-output neural network regression model to obtain hydrogen leakage quantitative parameters based on the weighted fusion feature vectors; and updating the memory cell bank based on the environmental information data, the hydrogen leakage position and the hydrogen leakage quantitative parameter. The accuracy, reliability and long-term stability of hydrogen leakage diagnosis can be improved.

This invention discloses a screening method, cell line, application, and cell bank for non-tumorigenic MDCK monoclonal strains, belonging to the field of biotechnology. The screening method includes: serum-free acclimation culture of a heterogeneous MDCK cell population; monoclonal isolation of the acclimated cell population to obtain candidate monoclonal cell lines; tumorigenicity screening by inoculating candidate monoclonal cell lines into immunodeficient animals to select non-tumorigenic cell lines; and viral susceptibility evaluation of the non-tumorigenic cell lines to select cell lines with predetermined susceptibility to a predetermined virus. This MDCK monoclonal cell line is non-tumorigenic. This invention addresses the risks of population heterogeneity and potential tumorigenicity in existing MDCK cell lines while ensuring viral production efficiency, providing an ideal cell platform for producing safer and quality-controlled viral vaccines.

In the various aspects and embodiments, the present disclosure provides cell populations or cell “banks” thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specific populations. In the various aspects and embodiments, the cell banks and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the cell banks by gene editing, and methods for cell therapy involving cells or tissues derived from the cell banks (including but not limited to hematopoietic stem cells, or “HSCs”, progenitors, or progenies thereof).

The invention discloses a stably produced mesenchymal stromal cell exosome containing anti-inflammatory miRNA effective components and a preparation method and application of the mesenchymal stromal cell exosome. The preparation method comprises the following steps: S1, obtaining placenta tissues, and performing isolated culture on primary placenta mesenchymal stromal cells; s2, constructing an immortalized placenta mesenchymal matrix cell line through a lentivirus transduction hTERT gene; s3, culturing the immortalized placenta mesenchymal matrix cell line in a serum-free culture medium, and collecting a cell supernatant; s4, the obtained supernate is sequentially subjected to centrifugation, PEG precipitation and ultrafiltration concentration, and exosome is extracted. According to the invention, hTERT immortalized human placenta mesenchymal stromal cells (iMSC022) of a single donor are adopted as a production source of the exosome (Exo), so that the application limitation of traditional primary cells is remarkably broken through. Compared with a mode that a primary mesenchymal stromal cell (MSC) needs to depend on multi-donor mixing to construct a cell bank due to limited multiplication capacity, the iMSC022 has high homogeneity after lentiviral transfection and resistance screening.

The application discloses a rhabdovirus-free Sf9 cell screening method of double pretreated conditioned medium, relates to the technical field of biology, and obtains the rhabdovirus-free Sf9 cell by double pretreatment of the conditioned medium through cross-flow filtration and beta-propiolactone inactivation and hydrolysis, and combination of single cell cloning screening. The method realizes efficient virus interception and high-activity retention of nutritional factors, the single cell cloning formation rate is greater than 40%, and is suitable for virus-free cell bank construction and biological product production.

Disclosed is an in-vitro protocol for differentiating human induced pluripotent stem cells (hiPSCs) or human embryonic stem cells (hESC) to give rise to a definitive endoderm, followed by progression into anteriorized foregut endoderm that has the ability to give rise to both proximal and distal lung epithelial cells. The protocol not only offers great opportunities for the study of human development but also have tremendous potential for future clinical cell-based therapies. The protocol outlined here is used to differentiate hiPSCs into lung epithelial cell types through a process that faithfully recapitulates the stepwise events observed in-vivo. The was followed with the working cell bank of an hiPSC line made under current Good Manufacturing Practice (cGMP) conditions, a necessary step for the future clinical application of these cells.

The invention relates to a new method for producing BK-RiV-forte nanoparticles, which enables a higher yield of particulate compositions. The BK-RiV-forte nanoparticles produced differ in their composition from known BK-RiV particles. The BK-RiV-forte nanoparticles produced by the new method increase the diversity of the T-cell repertoire and have a wide range of applications in medicine, for example in the treatment of septic diseases, as well as wounds, tumors, strokes, and inflammatory processes of all kinds.

[Subject] An intermediate for the short-term and low-cost production of therapeutic iPS-T cell preparations with reduced allorecognition responses in patients receiving them and a cell bank containing the intermediate is provided. [Solution]　A cytotoxic lymphocyte expressing a variable region-deleted T cell receptor (TCR) comprising a first polypeptide and a second polypeptide, the first polypeptide including a constant region of a human TCRα chain or a fragment thereof, and not including a variable region of the human TCRα chain, the second polypeptide including a constant region of a human TCRβ chain or a fragment thereof, and not including a variable region of the human TCRβ chain, wherein, the cytotoxic lymphocyte lacks antigen specificity due to the expression of the variable region-deleted TCR; the cytotoxic lymphocyte is differentially induced from a pluripotent stem cell into which a nucleic acid encoding the variable region-deleted TCR is introduced from outside the cell; and the cytotoxic lymphocyte is an intermediate for producing antigen-specific iPS-T cells by introducing a nucleic acid encoding a receptor that recognizes an antigen from outside the cell and expressing the receptor; and a cell bank containing the cytotoxic lymphocytes.

Provided herein is a method for preparing a sequencing library containing nucleic acids from a plurality of single cells. In one embodiment, the sequencing library contains nucleic acids representing chromatin accessibility from a plurality of single cells. In one embodiment, the nucleic acids include three index sequences. In another embodiment, the present disclosure provides a method for characterizing rare events in isolated cells and nuclei. In an embodiment, providing can include providing a plurality of nuclei or cells in a plurality of compartments, each compartment containing a subset of nuclei or cells or representing a sample.

Disclosed is an in-vitro protocol for differentiating human induced pluripotent stem cells (hiPSCs) or human embryonic stem cells (hESC) to give rise to a definitive endoderm, followed by progression into anteriorized foregut endoderm that has the ability to give rise to both proximal and distal lung epithelial cells. The protocol not only offers great opportunities for the study of human development but also have tremendous potential for future clinical cell-based therapies. The protocol outlined here is used to differentiate hiPSCs into lung epithelial cell types through a process that faithfully recapitulates the stepwise events observed in-vivo. The was followed with the working cell bank of an hiPSC line made under current Good Manufacturing Practice (cGMP) conditions, a necessary step for the future clinical application of these cells.